2019 ANNUAL REPORT

TAKE CHARGE. GET SCREENED.

Health Screenings Save Lives.

Schedule today. | www.atlanticare.org/screening

Thank You!

Proud to Be Oncology Certified Nurse

AtlantiCare
The Cancer Care Institute

A member of Geisinger

Fox Chase Cancer Center Partner
Table of Contents

Oncology Program Leadership................................................................................................................................. 3
Quality Care Close to Home........................................................................................................................................ 4
Operations Leadership Corner................................................................................................................................. 5
2019 Highlights and Achievements .......................................................................................................................... 6
Genetic Counseling Corner....................................................................................................................................... 10
Advancing Cancer Care through Clinical Research................................................................................................. 11
Oncology Data Services............................................................................................................................................ 11
Cancer Registry Data – 2018 Analytic Cases........................................................................................................... 12
Outcomes.................................................................................................................................................................. 14
Outcomes: Quality Study........................................................................................................................................... 16
Nurse Navigator’s Corner.......................................................................................................................................... 17
Taking Care and Giving Back................................................................................................................................. 18
AtlantiCare Cancer Committee Members............................................................................................................... 19

Published December 2019
AtlantiCare Cancer Care Institute
A Fox Chase Cancer Center Partner

ONCOLOGY PROGRAM LEADERSHIP

James Wurzer, MD, PhD
Medical Director, Oncology Program
Medical Director, Radiation Oncology
Adjunct Associate Member, Radiation Oncology, Fox Chase Cancer Center

Neha Chawla, MD
Medical Director, Hematology/Medical Oncology

Magesh Sundaram, MD, MBA, FACS
Medical Director, Surgical Oncology

John D. Lorenzetti, MD, FACS
Medical Director, Breast Health Program

Frank Carpenter
Assistant Vice President, Oncology Services

Desiree Jangha, PhD, DABR
Director, Medical Physics, Radiation Therapy Services

Lacey Peterman
Director, Oncology Operations

Marcia McCulley, MBA
Oncology Program Manager
Community Outreach Coordinator

Maria Victoria Roque, BSN, RN, OCN
Clinical Manager, Medical Oncology

Kathryn Thomas, RN, BSN, OCN, CCRP
Supervisor, Oncology Clinical Research

Yanny Mejia, BSc, MBA
Oncology Practice & Revenue Cycle Manager

Cheryl Eget, CTR
Oncology Data Services Supervisor
QUALITY CARE, CLOSE TO HOME

A cancer diagnosis is deeply personal, and patients may feel as if they are on an island. At the AtlantiCare Cancer Care Institute, a Fox Chase Cancer Center Partner, we want our patients to know one thing above all others:

In this journey, you are not alone.

We have worked to create a healing environment dedicated to providing our community with access to the most advanced technologies available. As cancer treatment has evolved, so have we, offering a full spectrum of care that has grown to include state-of-the-art options such as CyberKnife, Varian TrueBeam linear accelerators and the latest in immunotherapy. Support services include an in-house pharmacy and lab, social services and genetics counseling.

Our commitment to bringing you the very latest in leading-edge technologies is matched only by our desire to provide a holistic treatment plan that cares for the body, mind and spirit. No two cancer diagnoses are identical, so we believe in creating individualized treatment plans that best target our patients’ unique situations. We have assembled an expert team whose sole purpose is to provide support when it is needed most.

This team-based approach brings together everyone needed to ensure patients can focus on what’s most important – their health and wellness. As a result, our multidisciplinary team of oncology nurse navigators, oncology- and research-certified nurses, clinical nutritionist, social workers, quality of life care, behavioral health, pain management specialists and other disciplines work in concert with physicians to provide quality care close to home. No one has to worry about traveling for treatment, because expert care is available right here in our backyard.

The Cancer Care Institute is well-equipped to care for a variety of cancer diagnoses ranging from complex gastrointestinal malignancies to cancers of the breast, prostate, respiratory system and more. We also provide for the full spectrum of care, recognizing that diagnosis and treatment are only two stops along the continuum of care. By also providing preventative screenings, genetic testing and counseling, support groups and survivorship programs, we work to provide peace of mind no matter where patients find themselves on their cancer journeys.

The AtlantiCare Cancer Care Institute’s commitment to quality and excellence has been nationally recognized with accreditation from the American College of Surgeons Commission on Cancer and the American College of Radiology. As we embark on our next decade, we are proud of the impact we have made in our community and look forward to building on our reputation for providing the quality, cutting-edge cancer care our patients need and deserve.

Sincerely,

James C. Wurzer, MD, PhD
Medical Director, Oncology Program;
Medical Director, Radiation Oncology,
AtlantiCare Cancer Care Institute,
a Fox Chase Cancer Center Partner

Adjunct Associate Member, Department
of Radiation Oncology, Fox Chase Cancer Center

Frank Carpenter
Assistant Vice President, Oncology Services
AtlantiCare Cancer Care Institute,
a Fox Chase Cancer Center Partner
Every day, the AtlantiCare Cancer Care Institute welcomes a patient for the first time. We know how important it is to create an optimal healing environment for our patients, and our passion is to provide expert care in a warm, comfortable setting. Our caregivers are experts at providing the treatment and resources patients need and deserve. With a deep legacy in our community, and as a Fox Chase Cancer Center Partner, we offer something else:

Hope.

At AtlantiCare, patients never face cancer alone. Our dedicated team is led by the region’s leading oncologists, who work closely with surgeons, oncology-certified nurses, pharmacists and the other expert members of the care team to create fully personalized treatment plans. Our patients don’t have to worry about getting lost in the system because they are at the center of every decision. Each patient and family that walks through our door becomes part of our extended family and enters a space where hope springs eternal.

In 2019 our Egg Harbor Township facility marked its 10-year anniversary with a community event titled “Where Hope Grows.” In partnership with AtlantiCare Healing Arts, we unveiled a survivor art project featuring photos that grace our halls and provide inspiration to patients, loved ones and staff daily. It is an important component of our holistic approach, which also includes dedicated nurse navigators, genetic counseling, clinical trials, education, counseling (social, nutritional and financial), spiritual support and transportation.

Every patient’s cancer journey is different, yet the one constant is the care provided at the Cancer Care Institute. With AtlantiCare as their partner, patients don’t have to search elsewhere for high-quality care.

Sincerely,

Lacey Peterman
Director, Oncology Operations

Desiree Jangha, PhD, DABR
Clinical Director, Medical Physics,
Radiation Therapy Services

Yanny Mejia, BSc, MBA
Oncology Practice & Revenue Cycle Manager

Marcia McCulley, MBA
Oncology Program Manager
Community Outreach Coordinator

Maria Victoria Roque, BSN, RN, OCN
Clinical Manager, Medical Oncology
2019 HIGHLIGHTS AND ACHIEVEMENTS

• The Oncology Program achieved:
  - American College of Surgeons Commission on Cancer (ACOS) re-accreditation, including five commendations.
  - Association of Community Cancer Centers (ACCC) program membership.
  - CEO (Chief Executive Officer) Cancer Gold Standard workplace wellness accreditation.
  - American College of Radiology accreditation for Egg Harbor Township and Cape May Court House campuses for Radiation Therapy, Gold Standard for Radiation Therapy accreditation.

• AtlantiCare continued its participation in the Centers for Medicare & Medicaid Services (CMS) Innovation Center’s Oncology Care Model (OCM), which focuses on care coordination, appropriateness and access for Medicare beneficiaries receiving chemotherapy.

• Celebrated the 10th Anniversary of the Egg Harbor Township Cancer Care Institute campus.

• Hired Surgical Oncologist and Interventional Pulmonologist.

• AtlantiCare began offering full-time genetic counseling services onsite at the Cancer Care Institute.

• Staffed by Oncology Certified Nurses (OCN®).

• AtlantiCare continues to expand its nurse navigation services to further enhance transitions of care.

• The AtlantiCare Cancer Care Institute provides inpatient coverage and consultation to current patients when in the hospital, including the hiring of an additional nurse practitioner to support that service.

• Began hosting monthly Us Too Prostate Support group, in addition to the Breast Cancer Support group.

PROVIDING EXCEPTIONAL CANCER CARE CLOSE TO HOME

When the diagnosis is cancer, patients don’t have to drive far to find exceptional care or to get a second opinion. From evaluation and diagnosis to treatment, psychosocial support, wellness services and recovery — everything patients and their families need is close by at the AtlantiCare Cancer Care Institute, a Fox Chase Cancer Center Partner.

AtlantiCare Cancer Care Institute is accredited by both the American College of Surgeons Commission on Cancer for our overall program and by the American College of Radiology for radiation therapy.

CLINICAL SERVICES

• Medical oncology and infusion services
• Radiation oncology
• Surgical oncology
• Clinical trials
• Diagnostic imaging
• Genetics counseling

SUPPORT SERVICES

• Oncology social workers
• Oncology nurse navigators
• Mammography scheduling
• Nutrition counseling with a registered dietitian
• Gilda’s Club at AtlantiCare: integrated psychosocial support programs on-site, including support groups, education and healthy lifestyle workshops that promote health and well-being
• Transportation to medical appointments
• Behavioral health services
• Pastoral care program
• Respecting Choices program for Advance Care Planning
• Financial counseling
• Community education and cancer screening
A DECADE OF EXCELLENCE

“We envisioned a bright, airy, comfortable, positive, hopeful, thoughtfully designed cancer treatment center that would help make the experience of cancer just a little bit better. Everything we envisioned has come to life, and then some.”

AtlantiCare was already offering comprehensive cancer care to our community when Craig Keyser, then chair of the ARMC Board of Trustees, spoke those words in June 2009. The occasion was the debut of a state-of-the-art Cancer Care Institute in Egg Harbor Township, an investment in our future as a leading provider of quality care.

Bright. Airy. Comfortable. Positive. Hopeful. The words remain as true today as when they were first spoken.

As cancer treatment and support services have evolved, AtlantiCare’s Cancer Care Institute has kept pace. A Fox Chase Cancer Center Partner, we continue to embrace cutting-edge technology and treatments to provide expert care to patients and their loved ones. To further bring care straight to the communities we serve, AtlantiCare opened an extension of the Cancer Care Institute in Cape May Court House in 2013.

Today, more people than ever are surviving cancer, and we have developed a robust survivorship program to assist patients in a variety of ways ranging from genetic testing to early detection, clinical trials to post-treatment support.

Looking to the future, we have assembled an expert team of cancer specialists whose passion is to help our patients navigate their cancer journeys from diagnosis through treatment and beyond. As the Cancer Care Institute embarks on its second decade, Chairman Keyser’s words speak to our philosophy as caregivers, and reinforce our continuing commitment to making the experience of cancer just a little bit better, one patient at a time.
ADVANCED RADIATION TREATMENT FOR ATLANTICARE PATIENTS

More than 50% of all cancer patients will require radiation therapy during their course of treatment. Radiation therapy may be used to destroy or shrink tumors, sometimes before or after cancer surgery, and to help alleviate symptoms. Each patient’s needs are different.

At the AtlantiCare Cancer Care Institute, a Fox Chase Cancer Center Partner, we offer the latest, safest and most effective radiation therapies to treat a wide range of cancers. Treatment is tailored to the specific type and location of your cancer, your general health and any other treatments you may be receiving. This specialized care is possible because we employ a variety of cutting-edge technology and advanced procedures. These include:

**Accuray CyberKnife®**

This robotic stereotactic radiosurgery system offers a painless, nonsurgical option for patients who have inoperable or surgically complex tumors. Using image guidance and computer-controlled robotics, CyberKnife delivers multiple beams of high-energy radiation to tumors from virtually any direction with ultra-precision. The CyberKnife system tracks a tumor’s position, detects any tumor or patient movement and automatically corrects the treatment delivery. Because it can treat tumors anywhere in the body with sub-millimeter accuracy, higher doses of radiation can be used per session, increasing the chance of successful treatment.

**Varian TrueBeam 2.7 and Trilogy Linear Accelerators**

Our state-of-the-art linear accelerators deliver radiation to the tumor with pinpoint precision, minimizing damage to surrounding healthy tissue. Options include:

- **Intensity-modulated radiation therapy (IMRT):** Delivers treatment precisely around the tumor by controlling the intensity of the radiation beams. This allows higher radiation doses to be focused on regions within the tumor while reducing the exposure to surrounding normal critical structures.

- **RapidArc®:** The fastest way to deliver radiation to the treatment area, using arc rotations around the patient.

- **Image-guided radiation therapy (IGRT):** Uses imaging techniques during radiation treatment to visualize the tumor and more accurately deliver the radiation.

- **Optical surface monitoring system (OSMS):** The newest image-guided technique available on the TrueBeam linear accelerators. This 3D imaging technology monitors the surface of the patient’s body to ensure more accurate delivery of radiation.

- **High-dose rate (HDR) brachytherapy:** Delivers radiation treatment by implanting radioactive seeds near or inside the tumor.

**Systemic radiation therapy:** Uses radiopharmaceuticals to therapeutically treat cancer or help alleviate symptoms. AtlantiCare offers the following therapies:

- Iodine-131 — used to treat thyroid illnesses
- Xofigo Radium-223 — used to treat prostate cancer that has spread to bone

AtlantiCare has earned full accreditation from the American College of Radiology (ACR), which means we meet the highest standards in patient safety and care.

Our board-certified radiation oncologists and technicians will work closely with you and your cancer care team to carefully plan and monitor each treatment to maximize success. We’ll also be right by your side through every phase of treatment to help you feel well and minimize changes to your normal routine.
BE YOUR OWN SUPERHERO:
EMPOWERING WOMEN TO TAKE CHARGE
OF THEIR HEALTH.

September 26, 2019 – Egg Harbor Township
100 women came together to learn about the
importance of screenings, genetics, healthy eating
and exercise to take charge of their health.

RIBBONS OF HOPE
May 31, 2019 – Assumption Regional
Catholic School, Galloway

The “Ribbons of Hope” field day event has raised close
to $20,000 in three years’ time to benefit the AtlantiCare
Cancer Care Institute, a Fox Chase Cancer Center Partner.
The event raises funds and awareness on the prevention,
detection, and treatment of cancer, while engaging
students to make a difference in their community.

ATLANTICARE CANCER CARE INSTITUTE
CELEBRATES AND HONORS SURVIVORS

June 4, 2019 – Egg Harbor Township
June 5, 2019 – Cape May Court House

During Cancer Survivors Week, events were held on
both campuses to celebrate patients and their families.
As part of the ShopRite LPGA Classic, LPGA pros
were on hand to lend friendly tips on putting.

HEROES OF HAIR
November 2019

AtlantiCare Heroes of Hair, a No Shave November
fundraising initiative, raised over $46,500 to support cancer
patients in the community. Hundreds of supporters skipped
a shave or halted a haircut in the name of fundraising.
The participants and those who supported them were
applauded at a celebration event at month’s end.
GENETIC COUNSELING CORNER

The AtlantiCare Cancer Care Institute introduced its genetic counseling program in 2018 in an effort to enhance the continuum of care for those at the highest risk of developing cancer. Licensed Genetic Counselor Laina Lusk, MMSc, LGC, works with physicians and nurses to identify patients who may benefit from genetic testing and coordinate their care.

In the past year, Lusk has helped to increase awareness of our genetic risk assessment program by presenting to local schools, support groups and physician practices. In addition, AtlantiCare has begun developing a clinic to support patients who test positive for a hereditary cancer syndrome. Our hope is to ensure that patients get the screenings and preventative services they need, and that they feel supported throughout the process. Our team includes providers from different specialties, as well as Lusk and our nurse navigators.

Most cancers occur by chance. However, if a person is born with certain changes in their genes, his or her risk for developing cancer can increase dramatically. Between 5% and 10% of cancers are caused by these genetic changes, called mutations, and finding a genetic mutation in a patient can have huge implications for the patient and his or her family. For example, the risk of developing breast cancer is 12.5% for the average woman, but as high as 80% for women with a mutation in the \textit{BRCA1} gene. In addition, women with \textit{BRCA1} mutations are at increased risk for ovarian and other cancers, while men with \textit{BRCA1} mutations are at increased risk for breast, prostate and other cancers as well.

As AtlantiCare’s genetic counselor, Lusk’s goal is to make genetics personal and easy to understand. When patients come for a genetic counseling session, she reviews their personal history of cancer, draws out their family tree, and provides relevant information about genetic testing and inherited risk. She works with patients to choose the right genetic test for them and, if they wish, they can then provide a saliva sample for testing right in her office. When results come back, she meets with patients to explain what the results mean in practical terms, and works with their providers to ensure they receive the care they need.

Laina Lusk, MMSc, LGC
Licensed Genetic Counselor
ADVANCING CANCER CARE THROUGH CLINICAL RESEARCH

Clinical trials (research studies) help medical researchers understand more about cancer and its treatment. Everything we know today about how to treat cancer was learned through a clinical trial. Through membership in the Geisinger National Community Oncology Research Program (NCORP), and as a Fox Chase Cancer Center Partner, AtlantiCare Cancer Care Institute is proud to offer patients the chance to take part in clinical trials that test new ways to diagnose and/or treat cancer and new ways to improve the lives of those with cancer.

Joining a clinical trial is a personal decision. People take part in clinical trials for many reasons, including gaining access to new treatments that are not yet widely available and wanting to make a difference for others who will be diagnosed with cancer in the future. Patients may choose to take part or not, and they are free to leave at any time.

The Supervisor of AtlantiCare Oncology Clinical Research helps patients understand what clinical trials may be available for them and their type of cancer. Research nurses explain everything patients need to know to make an informed decision about whether or not to take part.

For more information about clinical trials at the AtlantiCare Cancer Care Institute, call 609-677-7735.

ONCOLOGY DATA SERVICES

AtlantiCare Cancer Care Institute is accredited by the American College of Surgeons Commission on Cancer (CoC). The CoC is a consortium of professional organizations dedicated to improving the survival and quality of life for cancer patients by establishing evidenced-based national standards and by monitoring the quality of cancer care at accredited programs. The National Cancer Database (NCDB) is a nationwide cancer database of patients treated at CoC-accredited programs.

The Cancer Registry team at the AtlantiCare Cancer Care Institute is responsible for capturing a complete history, diagnosis, first course of treatment and health status for every cancer patient at AtlantiCare in a timely manner. Each patient is followed for the course of his or her lifetime after diagnosis. The Cancer Registry team also organizes and participates in multidisciplinary oncology conferences and supports the AtlantiCare Cancer Committee in addition to the cancer program.

AtlantiCare uses registry data for research and to evaluate patient outcomes and the allocation of resources within the cancer program. In addition, we use the data in our community health needs assessments and in our community education and outreach activities to address identified needs in the area. Registry data is submitted to the NCDB and to the New Jersey State Department of Health Cancer Registry for reporting of National Quality Measures.

The AtlantiCare Cancer Committee utilizes the NCDB’s accountability reporting tool to monitor our quality performance and outcomes, and to serve as a benchmark to focus quality improvement opportunities that support high-quality care.
## CANCER REGISTRY DATA – 2018 ANALYTIC CASES*

<table>
<thead>
<tr>
<th>PRIMARY SITE</th>
<th>TOTAL</th>
<th>MALE</th>
<th>FEMALE</th>
</tr>
</thead>
<tbody>
<tr>
<td>ORAL CAVITY &amp; PHARYNX</td>
<td>16</td>
<td>13</td>
<td>3</td>
</tr>
<tr>
<td>Tongue</td>
<td>5</td>
<td>5</td>
<td>0</td>
</tr>
<tr>
<td>Salivary Glands</td>
<td>2</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Floor of Mouth</td>
<td>1</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Gum &amp; Other Mouth</td>
<td>1</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Nasopharynx</td>
<td>2</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>Oropharynx</td>
<td>3</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>Hypopharynx</td>
<td>2</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>DIGESTIVE SYSTEM</td>
<td>153</td>
<td>91</td>
<td>62</td>
</tr>
<tr>
<td>Esophagus</td>
<td>8</td>
<td>7</td>
<td>1</td>
</tr>
<tr>
<td>Stomach</td>
<td>12</td>
<td>9</td>
<td>3</td>
</tr>
<tr>
<td>Small Intestine</td>
<td>4</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Colon Excluding Rectum</td>
<td>51</td>
<td>29</td>
<td>22</td>
</tr>
<tr>
<td>Cecum</td>
<td>9</td>
<td>5</td>
<td>4</td>
</tr>
<tr>
<td>Appendix</td>
<td>3</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>Ascending Colon</td>
<td>7</td>
<td>9</td>
<td>8</td>
</tr>
<tr>
<td>Hepatic Flexure</td>
<td>2</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>Transverse Colon</td>
<td>3</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>Descending Colon</td>
<td>2</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>Sigmoid Colon</td>
<td>13</td>
<td>8</td>
<td>5</td>
</tr>
<tr>
<td>Large Intestine, NOS</td>
<td>2</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Rectum &amp; Rectosigmoid</td>
<td>20</td>
<td>11</td>
<td>9</td>
</tr>
<tr>
<td>Rectosigmoid Junction</td>
<td>9</td>
<td>6</td>
<td>3</td>
</tr>
<tr>
<td>Rectum</td>
<td>11</td>
<td>5</td>
<td>6</td>
</tr>
<tr>
<td>Anus, Anal Canal &amp; Anorectum</td>
<td>10</td>
<td>3</td>
<td>7</td>
</tr>
<tr>
<td>Liver &amp; Intrahepatic Bile Duct</td>
<td>17</td>
<td>13</td>
<td>4</td>
</tr>
<tr>
<td>Liver</td>
<td>16</td>
<td>13</td>
<td>3</td>
</tr>
<tr>
<td>Intrahepatic Bile Duct</td>
<td>1</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Gallbladder</td>
<td>4</td>
<td>1</td>
<td>3</td>
</tr>
<tr>
<td>Other Biliary</td>
<td>1</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Pancreas</td>
<td>27</td>
<td>15</td>
<td>12</td>
</tr>
<tr>
<td>RESPIRATORY SYSTEM</td>
<td>134</td>
<td>70</td>
<td>64</td>
</tr>
<tr>
<td>Nose, Nasal Cavity &amp; Middle Ear</td>
<td>1</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Larynx</td>
<td>8</td>
<td>7</td>
<td>1</td>
</tr>
<tr>
<td>Lung &amp; Bronchus</td>
<td>124</td>
<td>61</td>
<td>63</td>
</tr>
<tr>
<td>Trachea, Mediastinum &amp; Other Respiratory Organs</td>
<td>1</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>SOFT TISSUE</td>
<td>3</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>Soft Tissue (including Heart)</td>
<td>3</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>SKIN EXCLUDING BASAL &amp; SQUAMOUS</td>
<td>9</td>
<td>8</td>
<td>1</td>
</tr>
<tr>
<td>Melanoma – Skin</td>
<td>8</td>
<td>7</td>
<td>1</td>
</tr>
<tr>
<td>Other Non-Epithelial Skin</td>
<td>1</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>BREAST</td>
<td>191</td>
<td>0</td>
<td>191</td>
</tr>
<tr>
<td>Breast</td>
<td>191</td>
<td>0</td>
<td>191</td>
</tr>
</tbody>
</table>
### PRIMARY SITE

<table>
<thead>
<tr>
<th>PRIMARY SITE</th>
<th>TOTAL</th>
<th>MALE</th>
<th>FEMALE</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>FEMALE GENITAL SYSTEM</strong></td>
<td>44</td>
<td>0</td>
<td>44</td>
</tr>
<tr>
<td>Cervix Uteri</td>
<td>10</td>
<td>0</td>
<td>10</td>
</tr>
<tr>
<td>Corpus &amp; Uterus, NOS</td>
<td>29</td>
<td>0</td>
<td>29</td>
</tr>
<tr>
<td>Corpus Uteri</td>
<td>25</td>
<td>0</td>
<td>25</td>
</tr>
<tr>
<td>Uterus, NOS</td>
<td>4</td>
<td>0</td>
<td>4</td>
</tr>
<tr>
<td>Ovary</td>
<td>4</td>
<td>0</td>
<td>4</td>
</tr>
<tr>
<td>Vulva</td>
<td>1</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td><strong>MALE GENITAL SYSTEM</strong></td>
<td>105</td>
<td>105</td>
<td>0</td>
</tr>
<tr>
<td>Prostate</td>
<td>105</td>
<td>105</td>
<td>0</td>
</tr>
<tr>
<td>Testis</td>
<td>1</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Other Male Genital Organs</td>
<td>1</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td><strong>URINARY SYSTEM</strong></td>
<td>32</td>
<td>23</td>
<td>9</td>
</tr>
<tr>
<td>Urinary Bladder</td>
<td>23</td>
<td>17</td>
<td>6</td>
</tr>
<tr>
<td>Kidney &amp; Renal Pelvis</td>
<td>9</td>
<td>6</td>
<td>3</td>
</tr>
<tr>
<td><strong>BRAIN &amp; OTHER NERVOUS SYSTEM</strong></td>
<td>25</td>
<td>10</td>
<td>15</td>
</tr>
<tr>
<td>Brain</td>
<td>18</td>
<td>6</td>
<td>12</td>
</tr>
<tr>
<td>Cranial Nerves, Other Nervous System</td>
<td>7</td>
<td>4</td>
<td>3</td>
</tr>
<tr>
<td><strong>ENDOCRINE SYSTEM</strong></td>
<td>21</td>
<td>5</td>
<td>16</td>
</tr>
<tr>
<td>Thyroid</td>
<td>16</td>
<td>3</td>
<td>13</td>
</tr>
<tr>
<td>Other Endocrine including Thymus</td>
<td>5</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td><strong>LYMPHOMA</strong></td>
<td>29</td>
<td>20</td>
<td>9</td>
</tr>
<tr>
<td>Hodgkin Lymphoma</td>
<td>1</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Non-Hodgkin Lymphoma</td>
<td>28</td>
<td>19</td>
<td>9</td>
</tr>
<tr>
<td>NHL - Nodal</td>
<td>16</td>
<td>11</td>
<td>5</td>
</tr>
<tr>
<td>NHL - Extranodal</td>
<td>12</td>
<td>8</td>
<td>4</td>
</tr>
<tr>
<td><strong>MYELOMA</strong></td>
<td>6</td>
<td>2</td>
<td>4</td>
</tr>
<tr>
<td>Myeloma</td>
<td>6</td>
<td>2</td>
<td>4</td>
</tr>
<tr>
<td><strong>LEUKEMIA</strong></td>
<td>14</td>
<td>11</td>
<td>3</td>
</tr>
<tr>
<td>Lymphocytic Leukemia</td>
<td>7</td>
<td>7</td>
<td>0</td>
</tr>
<tr>
<td>Acute Lymphocytic Leukemia</td>
<td>2</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>Chronic Lymphocytic Leukemia</td>
<td>3</td>
<td>3</td>
<td>0</td>
</tr>
<tr>
<td>Other Lymphocytic Leukemia</td>
<td>2</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>Myeloid &amp; Monocytic Leukemia</td>
<td>4</td>
<td>3</td>
<td>1</td>
</tr>
<tr>
<td>Other Leukemia</td>
<td>3</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>Other Acute Leukemia</td>
<td>1</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Aleukemic, Subleukemic &amp; NOS</td>
<td>2</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td><strong>MESOTHELIOMA</strong></td>
<td>2</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Mesothelioma</td>
<td>2</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td><strong>MISCELLANEOUS</strong></td>
<td>29</td>
<td>16</td>
<td>13</td>
</tr>
<tr>
<td>Miscellaneous</td>
<td>29</td>
<td>16</td>
<td>13</td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td>816</td>
<td>378</td>
<td>438</td>
</tr>
</tbody>
</table>

*Cases for which AtlantiCare provided the initial diagnosis of cancer and/or for which AtlantiCare contributed to the patient’s first course of treatment.*
QUALITY PERFORMANCE MEASURES

Below are the American College of Surgeons Commission on Cancer (CoC) quality performance benchmark standards comparing AtlantiCare with other CoC organizations in New Jersey and the United States.

CoC standard for surgery is not the first course of treatment for node positive lung cancer

Surgery is not the first course of treatment for cN2, M0 lung cases.

CoC standard for regional lymph nodes in surgically resected colon cancer

At least 12 regional lymph nodes are removed and pathologically examined for resected colon cancer.

CoC standard for breast-conserving surgery and radiation therapy in breast cancer

Radiation is administered within 1 year (365 days) of diagnosis for women under the age of 70 receiving breast conservation surgery for breast cancer.
Vital to the success of the AtlantiCare Cancer Care Institute is continuous evaluation of performance in order to improve patient outcomes, emphasizing a professional commitment to safety and quality. This year, the Cancer Committee designated stage II-III breast carcinoma for an in-depth analysis to assess and to verify that cancer program patients are evaluated and treated according to evidence-based national treatment guidelines. Breast cancer is the leading cause of cancer death in women worldwide. This formal review with analysis results represents a full evaluation of 28 patients diagnosed with 30 stage II-III breast cancers between November 2017 and October 2018. Results were presented to the Cancer Committee and documented in Cancer Committee minutes.

Initial evaluation of patients presenting to the AtlantiCare Cancer Care Institute with the diagnosis of breast cancer was considered appropriate when the following criteria were documented/met: history/physical examination, diagnostic bilateral mammogram, axillary assessment with exam (ultrasound or other imaging as necessary), pathology review, determination of estrogen/progesterone receptor (ER/PR) and HER2 status, genetic counseling if patient is at risk for hereditary breast cancer, distress assessment, and pregnancy test in all women of childbearing potential. Breast MRI was considered optional, but special consideration was given for mammographically occult tumors. Additional workup prior to systemic therapy included CBC, comprehensive metabolic panel, and either chest and abdominal diagnostic CT with contrast and bone scan or PET/CT (optional). The review of the workup of these patients was concordant with evidence-based national guidelines in all cases. Patients were staged appropriately utilizing American Joint Committee on Cancer (AJCC) staging methods. The eighth edition of the TNM staging system, effective as of January 1, 2018, includes prognostic stage groups, which incorporate biomarker testing.

Treatment for this patient cohort varied based on stage and biomarker status, and included lumpectomy or mastectomy with surgical axillary staging, endocrine and/or systemic therapy, and breast radiation therapy where indicated. Treatment plan criteria were considered met if the recommended surgery, endocrine and/or systemic therapy, and breast radiotherapy was documented as completed, or as recommended but not completed as planned for reasons stated in the medical record (i.e. contraindication, comorbidities, treatment toxicity, patient death, relocation, refusal or non-compliance). Review of treatment plans for these patients was concordant with evidence-based national guidelines in all cases.

In summary, this analysis confirms compliance with national guidelines. Collaborative coordination of care between medical oncology, surgical oncology, pathology, diagnostic radiology and radiation oncology was evident during case review at weekly multidisciplinary Breast Oncology Conference. High-quality clinical services, including state-of-the-art pretreatment evaluation, staging, individualized treatment and clinical follow up were verified as provided for AtlantiCare stage II-III breast cancer patients.
INTRODUCTION: Advance care planning (ACP) is often initiated too late, when patients are well into a serious illness. This leads to added stress and high resource utilization at the end of life. Although advance directives (AD) and ACP are integral to providing quality cancer care, their inclusion into the standard of care for these patients remains a challenge. AtlantiCare’s Advanced Illness Management (AIM) Program provided training to the Cancer Care Institute team to promote dialogue with patients on ACP and encourage them to complete an AD. Despite this, a generated report from January to March 2019 showed that out of 504 patients aged 65 years and older, only 16.1% possessed either an AD or a Practitioner Orders for Life-sustaining Treatment (POLST) in their electronic medical record (EMR).

RESULTS: The review showed that 60 (11.9%) patient charts on the list with no AD actually had the following: 35 charts had AD scanned into the chart; 13 had POLST; and three had both POLST and AD. Another nine (2.1%) charts had documentation that the patient had an existing AD that would be brought in on the next visit. A chart review on those on the list with AD showed that on seven of the charts, no AD or POLST was found. These are discrepancies between the generated report and the chart review. Part of documenting in the Intake Form includes checking off a box that changes the patient banner bar to count towards the patient having an AD when a report is generated. Checking the Clinical Document tab to see if an AD or a POLST was previously scanned in under the Advance Care Planning section is an important step in documentation. It was also noted that in the Patient Intake Form, the question “Reason Advance Directive (was) not provided” often remained unanswered. When asked, this question provides an opportunity for the nurse to discuss the importance of having an AD and/or POLST.

CORRECTIVE ACTION PLAN: A unit-based nursing team was formed to determine the best process to document AD in the EMR and coordinate with AIM to re-educate staff on ACP and AD for a better discussion with patients. The team will monitor the results of the proposed process improvement by generating a monthly report of AD in the EMR. This will also serve as one of the indicators under Best Quality in the AtlantiCare Cancer Care Institute Scorecard.
Ensuring a seamless care experience for patients and their families.

When you’re fighting cancer, it’s reassuring to have an advocate in your corner to help with appointment scheduling, specialist referrals, treatment side effects and other aspects of your care. At the AtlantiCare Cancer Care Institute, a Fox Chase Cancer Center Partner, patients are personally guided through the continuum of care by oncology nurse navigators such as Evelyn Darretta, BSN, RN, OCN, and Tracie Rodriguez, RN, OCN.

Evelyn is dedicated full time to assisting women and men diagnosed with breast cancer, while Tracie advocates for patients with complex GI, lung and prostate cancers, as well as others who need coordination of care. Both are integral members of the multidisciplinary patient care team working one on one with patients and their loved ones to coordinate all the necessary details before, during and after treatment.

“My goal is to always treat my patients with the care I would want my family or myself to receive. When dealing with a cancer diagnosis, patients and their families endure difficult emotional and physical struggles. Comfort and security can be felt when knowing how to prepare and plan for your care. I want to be there to help individuals through their journey.”

Evelyn brings more than 20 years of medical oncology nursing experience to her role as breast nurse navigator on the AtlantiCare team. In this role, Evelyn serves as a patient advocate and care coordinator for women and men diagnosed with breast cancer and their personal support systems. She is highly skilled in administering chemotherapy and biotherapy in an outpatient setting, and in providing supportive care to patients throughout their therapy.

“I have dedicated myself to providing individualized care to patients and their family members through the treatment, journey and beyond. I want those in my care to feel part of a family with me and with our team to help decrease their fear and heal with less worry during this stressful time.”

Tracie joined AtlantiCare Regional Medical Center (ARMC) in 2002 and has provided patient care in various clinical areas, including the Oncology department at ARMC Mainland Division, the outpatient and inpatient operating rooms and recovery room at ARMC Surgery Center, and the Radiation Oncology department of the AtlantiCare Cancer Care Institute. Most recently, she was the lead registered nurse working directly with James Wurzer, MD, PhD, medical director of Radiation Oncology.

In addition to providing individualized patient education, our navigators assist by enhancing access to services and helping patients overcome any barriers to care, such as transportation, insurance issues or language translation. Evelyn and Tracie also promote the emotional and physical well-being of patients in addition to focusing on their medical needs.
TAKING CARE AND GIVING BACK

In addition to specialized medical services for the diagnosis and treatment of cancer, community education and outreach are important elements in the service continuum at AtlantiCare Cancer Care Institute. AtlantiCare’s community outreach in 2019 included support groups, cancer prevention and screening programs, and support of events and nonprofit organizations that benefit community members in the fight against cancer.

Community Education and Screening

- Health fairs, workshops and educational lectures on various cancer-related topics
- Men’s Health prostate screening
- Screening mammograms
- Skin cancer health assessments and prevention education events
- Great American Smokeout
- Somers Point Beach Concert Series
- Tobacco Cessation classes
- Colorectal Cancer Awareness activities

Event Sponsorship and Participation

- American Cancer Society events
- American Heart Association
- Business at the Beach Expo, CMC Chamber of Commerce
- Every Breath Counts, Lung Cancer Walk/Run
- Gilda’s Club South Jersey events
- Heroes of Hair, No Shave November
- National Night Out
- Ribbons of Hope
- Christina M. Rush Foundation
- Ruth Newman Shapiro Cancer and Heart Fund events
- Shirley Mae Run and Michael J. Walk
- Susan G. Komen events
- Tara Miller Melanoma Foundation Gala
- Us Too Prostate Support Group
- Great American Smokeout
- Somers Point Beach Concert Series
- Tobacco Cessation classes
- Colorectal Cancer Awareness activities
ATLANTICARE CANCER COMMITTEE MEMBERS

The AtlantiCare Cancer Committee is composed of primary and specialty care physicians, as well as hospital staff and providers with a direct role in caring for our oncology patients. The multidisciplinary committee meets regularly to review and evaluate the quality and direction of the overall oncology program and makes recommendations for improvement.

Required Physician Members

Mitchell Brezel, MD
Diagnostic Radiologist

Neha Chawla, MD
Medical Director, Medical Oncologist

Magesh Sundaram, MD, MBA, FACS
Medical Director, Surgical Oncology
Cancer Liaison Physician

William Todd, MD
Pathologist

James Wurzer, MD, PhD
Medical Director, Oncology Program
Medical Director, Radiation Oncology
Cancer Committee Chairman
Adjunct Associate Member, Radiation Oncology, Fox Chase Cancer Center

Required Non-Physician Members

Tom Blanco
Director of Regulatory and Accreditation Quality Management Representative

Frank Carpenter
Assistant Vice President, Oncology Services

Elizabeth Eble, DNP, APN
Palliative Care

Cheryl Eget, CTR
Cancer Registry Quality Coordinator
Supervisor, Oncology Data Services

Loreta Garretson, MD
Hematology/Medical Oncology

Samantha Hill, MSW
Psychosocial Services Coordinator
Social Worker

Laina Lusk, MMSc, LGC
Genetic Counselor

Marcia McCulley, MBA
Oncology Program Manager
Community Outreach Coordinator

Nancy McGrath, RHIT, CTR
Cancer Conference Coordinator

Devon McKenzie, MD
Hematology/Medical Oncology

Maria Victoria Roque, BSN, RN, OCN
Quality Improvement Coordinator
Clinical Manager, Medical Oncology

Kathryn A. Thomas, RN, BSN, OCN, CCRP
Supervisor, Oncology Clinical Research

Additional Members

Janine S. Begasse, MBA, BSN, RN, CPHQ
Corporate Director of Quality and Regulatory & Accreditation

Bruno Dantas, MD
Pathologist

Evelyn Darretta, BSN, RN, OCN, ONN-CG
Nurse Navigator

Vicki DiStephano, RN, OCN
Radiation Nurse

Bonnie Duboff
Registered Dietitian

Kelly Filchner, MSN, RN, OCN, CCRC
Fox Chase Cancer Center Liaison

Audrey Heist, MPH, RD
Director of Health Engagement

Juliann Henry, MDiv
Pastoral Care Representative

Desiree Jangha, PhD, DABR
Director, Medical Physics, Radiation Therapy Services

David Levi, MD
Diagnostic Radiologist

John Lorenzetti, MD, FACS
Medical Director of Breast Program
Breast Surgeon

Maria Marine Ortiz-Sanchez
Oncology Data Services

Yanny Mejia, BSc, MBA
Oncology Practice & Revenue Cycle Manager

Natalie Menard
American Cancer Society Representative

Lacey Peterman
Director, Oncology Operations

Valmarie Ramos, MD
Hematology/Medical Oncology

Tracie Rodriguez, RN, OCN, ONN-CG
Nurse Navigator

Kelly Sanders, BSN, RN
Hospice

Cathy Sutman, MSW
Psychosocial Services Coordinator
Social Worker

Denise Sutor, RN
Oncology Clinical Research Associate

Vasthi Wilson, MD, MSc
Radiation Oncologist
AtlantiCare Health Park
2500 English Creek Avenue, Building 400
Egg Harbor Township, NJ 08234

106 Court House South Dennis Road, Building 200
Cape May Court House, NJ 08210

1-888-569-1000
www.atlanticare.org/cancer